Search This Blog

Tuesday, November 2, 2021

BioNTech to Present New Clinical Data from First-in-Class CAR-T Program

 BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"), a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today announced that new clinical data from the first-in-human Phase 1/2 trial evaluating the Company's novel CAR-T cell therapy candidate, BNT211, will be presented in an oral presentation. The presentation is scheduled for the late-breaking abstract poster session at the 36(th) Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held both in person and virtually from November 10 - 14, 2021.

"Our goal is to leverage our understanding of immunology and tumor biology together with our advanced technologies to provide cancer patients with novel treatments," said Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. "Claudin-6 is a new target that we believe is well-suited for CAR-T therapy and presents a differentiated avenue for the treatment of solid tumors. We appreciate the opportunity to present initial data from our first-in-human study of the CAR-T product candidate to leading immuno-oncology experts in this prestigious late-breaking forum, which further underline the potential of our technology."

BNT211 is an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin 6 (CLDN6) and the first CAR-T product candidate in the Company's clinical development. BNT211 is currently being investigated as a monotherapy and in combination with a CLDN6-encoding mRNA-based vaccine (CARVac) in a first-in-human Phase 1/2 clinical trial

For more information, please visit https://www.globenewswire.com/Tracker?data=mPha8Ludm7WWUzo93omVJFw3-C9oJIc9SAjfIcyUdW_6LKSt2XqWNUoQOOPN0siuoAhkKZX9NM2plQLRW19Drw== www.BioNTech.de

https://www.marketscreener.com/quote/stock/BIONTECH-SE-66771992/news/Press-Release-BioNTech-to-Present-New-Clinical-Data-from-First-in-Class-CAR-T-Program-BNT211-in-La-36856352/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.